BTIG Reiterates Buy on Abbott Laboratories, Maintains $131 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 78.0%

Neg 0% Neu 78% Pos 0%

BTIG analyst Marie Thibault reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $131 price target.

Comments

No comments yet. Be the first!